FDA allow Flibanserin to improve female sex drive

Finally, Food and Drug Administration approved the use of “female Viagra”, to satisfy women’s sexual events.

U.S. Food and Drug Administration or FDA approved flibanserin, 18 August 2015, use for improving female sex drive. A drug that could increase or boost women’s sexual needs, studied as non-hormonal treatment for pre-menopausal women having hypoactive sexual desire disorder.

This commonly refers to female Viagra, originally developed as antidepressant. It will be marketed under the name Addyi by Sprout Pharmaceuticals and works through targeting part of the central nervous system’s sexual response.

Sprout Pharmaceuticals to label indication for the drug said, expected to make Addyi available to patients starting in mid-October, gynecologists will be the main prescribers, but it could also by prescribed by primary care physicians and mental health professionals who specialize in sexual health.

Director of the FDA’s Center for Drug Evaluation and Research, Janet Woodcock, M.D. stated, “Today’s approval provides women distressed by their low sexual desire with an approved treatment option.”, “The FDA strives to protect and advance the health of women, and we are committed to supporting the development of safe and effective treatments for female sexual dysfunction.”, “Patients and prescribers should fully understand the risks associated with the use of Addyi before considering treatment.”

According to US Food and Drug Administration , drug to be sold under the brand name Addyi and made by privately held Sprout Pharmaceuticals, will only be available through certified and specially trained health care professionals and pharmacies due to its safety issues.

Even the Score, an advocacy group that pressured the FDA to approve flibanserin, emphasized that several approved treatments for male sexual dysfunction exist, while no such treatment for women was available.

Reactions associated upon taking flibanserin or Addyi includes dizziness, somnolence or sleepiness, nausea, fatigue, insomnia and dry mouth. FDA’s analysis found low blood pressure and fainting might some side effect of the said drug. IMAGE/AP


Like this article? Please spread the story.